Research Article

Identification of Active Compounds of Mahuang Fuzi Xixin Decoction and Their Mechanisms of Action by LC-MS/MS and Network Pharmacology

Xiao Liang,^{1,2,3} Chang-Shun Liu,^{1,2,3} Ting Xia,^{1,2,3} Qing-Fa Tang ^{1,2,3}, and Xiao-Mei Tan ^{1,2,3}

¹School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China

²Guangdong Provincial Key Laboratory of Chinese Medicine Pharmaceuticals, Guangzhou, China

³Guangdong Provincial Engineering Laboratory of Chinese Medicine Preparation Technology, Guangzhou, China

Correspondence should be addressed to Xiao-Mei Tan; tanxm_smu@163.com

Received 17 January 2020; Revised 30 April 2020; Accepted 6 May 2020; Published 25 May 2020

Academic Editor: Olumayokun A. Olajide

Copyright © 2020 Xiao Liang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The decoction is an important dosage form of traditional Chinese medicine (TCM) administration. The Mahuang Fuzi Xixin decoction (MFXD) is widely used to treat allergic rhinitis (AR) in China. However, its active compounds and therapeutic mechanisms are unclear. The aim of this study was to establish an integrative method to identify the bioactive compounds and reveal the mechanisms of action of MFXD. LC-MS/MS was used to identify the compounds in MFXD, followed by screening for oral bioavailability. TCMSP, BindingDB, STRING, DAVID, and KEGG databases and algorithms were used to gather information. Cytoscape was used to visualize the networks. Twenty-four bioactive compounds were identified, and thirty-seven predicted targets of these compounds were associated with AR. DAVID analysis suggested that these compounds exert their therapeutic effects by modulating the Fc epsilon RI, B-cell receptor, Toll-like receptor, TNF, NF- κ B, and T-cell receptor signaling pathways. The PI3K/AKT and cAMP signaling pathways were also implicated. Ten of the identified compounds, quercetin, pseudoephedrine, ephedrine, β -asarone, methylephedrine, α -linolenic acid, cathine, ferulic acid, nardosinone, and higenamine, seemed to account for most of the beneficial effects of MFXD in AR. This study showed that LC-MS/MS followed by network pharmacology analysis is useful to elucidate the complex mechanisms of action of TCM formulas.

1. Introduction

Allergic rhinitis (AR), an immunoglobulin E- (IgE-) mediated inflammatory disease, seriously impairs the quality of life of patients [1]. Epidemiological surveys show that AR affects more than 20% of the world's population and its incidence has progressively increased in developing countries [2]. Currently, treatments based on Western medicine alleviate the symptoms of AR but do not cure. Once drug treatments stop, the disease relapses [3]. Traditional Chinese medicine (TCM) has long been used as effective therapeutic interventions in Asia, particularly China [4]. TCM is primarily based on the use of compound formulas, utilizing a combination of herbs or their extracts for improved efficacy.

Research into the active and effective compounds of TCM promotes the development and design of new therapeutic drugs.

The decoction is the main form of TCM administration. The identification of the chemical components in a decoction underpins research on the mechanism of action of TCM. Mahuang Fuzi Xixin decoction (MFXD), a classical Chinese herbal formula, is widely used to treat AR. MFXD consists of Mahuang (*Herba Ephedrae*), Fuzi (*Radix aconiti lateralis praeparata*), and Xixin (*Radix et Rhizoma Asari*), which are boiled in water at specific proportions before administration. Pharmacological studies have shown that MFXD exerts anti-inflammatory and antiallergic effects by preventing the release of mediators from macrophages and

mast cells and inhibiting the production of interferon gamma and interleukin (IL)-4 [5, 6]. MFXD also suppresses Th2 cytokine production and regulates the balance of Th1 and Th2 responses [7]. Using collected compounds and targets from databases and references, Tang constructed a network that shows the interactions of components and targets and verified the pharmacological activity of four components (salsolinol, pseudoephedrine, dibutyl phthalate, and herbacetin) of MFXD *in vitro* [8]. However, to our knowledge, there have been no comprehensive studies of the compounds in the decoction prepared from MFXD and their potential therapeutic mechanism in AR.

Network pharmacology is a new field that integrates pharmacological information, omics, and systems biology [9]. It is based on the concept that targeting multiple nodes in interconnected systems, rather than individual nodes, generates information for the identification of a drug with better efficacy and fewer adverse effects. TCM formulas commonly comprise a mixture of several herbs and ingredients that deliver synergistic effects by targeting multiple targets and pathways and modulating the links between pathways. Thus, network pharmacology, which elucidates interactions between multiple compounds and targets, is particularly suited for investigating the activities of TCM [10, 11]. Currently, drug discovery is rapidly evolving towards systematic and multiparmacological approaches to address the poor efficacy, loss of efficacy, and development of drug resistance when single compounds are used to target single therapeutic targets [12, 13]. Research is now focused on the simultaneous investigation of targets in the context of entire biological networks [14]. This network pharmacology approach to drug discovery and design may identify effective drugs from herbal medicines.

Therefore, the aim of this study was to identify the active compounds in the decoction prepared from MFXD to investigate their potential synergistic effects on cellular signaling pathways that are associated with AR. In this study, the combinatorial approach of LC-MS/MS followed by network pharmacology analysis was established to identify the active chemical compounds in the decoction prepared from MFXD and their potential pharmacological mechanism in AR. This research considers bioactive compounds, protein targets, protein-protein interactions, genes, and signaling pathways to elucidate the mechanisms responsible for the curative effects of MFXD in AR.

2. Materials and Methods

2.1. Materials. HPLC-grade acetonitrile and methanol were procured from Merck (Darmstadt, Germany). Formic acid was procured from Sigma-Aldrich (MO, USA). Other chemicals were of analytical grade.

The decocting pieces of Mahuang, Fuzi, and Xixin were purchased from Kangmei Pharmaceutical Co., Ltd. (Guangzhou, China) and met the standards of the Chinese Pharmacopoeia. Voucher specimens (no. 20191117) were deposited at the authors' laboratory at Southern Medical University.

2.2. Preparation of MFXD. MFXD consisted of Mahuang, Fuzi, and Xixin at a weight ratio of 2:3:1. Mahuang was immersed in distilled water (15 times the total weight) for 30 min and boiled for 20 min. Fuzi and Xixin were then added to the suspension, which was simmered for another 90 min. The liquid extract obtained was concentrated to 1.52 g/mL under reduced pressure.

2.3. LC-MS/MS Analyses. LC-MS/MS was carried out using a UPLC-Orbitrap-HRMS platform (Thermo Fisher) with a Waters ACQUITY UPLC HSS T3 Column (100 mm × 2.1 mm, 1.8 μ m). The mobile phases consisted of acetonitrile (A) and 0.1% aqueous formic acid (v/v) (B) using a gradient elution of 0% A at 0–1 min, 0–20% A at 1–2 min, 20–50% A at 2–12 min, 50–95% A at 12–15 min, and 95–100% A at 15–20 min. The flow rate was set at 0.4 mL/min, and the column temperature was maintained at 30°C. The injection volume was 5 μ L. The electrospray ionization source was set to positive and negative modes. The mass range scanned was 100–1000 m/z. MS data were collected with Thermo Xcalibur software (version 4.0).

2.4. Construction of the Chemical Ingredient Database. We processed the chromatogram by matching the data with an in-house Orbitrap Traditional Chinese Medicine Library (OTCML), which provided a list of compounds with their formulas and MS/MS fragment modes. Based on errors less than 5 ppm and MS/MS fragment matching, we identified compounds in decoction prepared from MFXD.

2.5. Oral Bioavailability (OB) Screening. OB is an important pharmacokinetic property used to assess the rate and percentage of an orally administered drug that has been absorbed into the blood circulation to produce pharmacological effects. Important parameters of the identified compounds, such as Caco-2 cell permeability, human intestinal absorption (HIA), and OB limits F (F-20%, F-30%), were screened using ADMETlab, a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database [15].

2.6. Potential AR-Associated Targets of the Compounds in MFXD. Predicting whether a compound interacts with intended targets is a critical phase of drug discovery [16]. The targets of compounds in MFXD were obtained from the Traditional Chinese Medicine System Pharmacology (TCMSP, <http://lsp.nwu.edu.cn/tcmsp.php>) and BindingDB (<https://www.bindingdb.org/bind/index.jsp>) databases. After the deletion of redundant hits, the remaining protein targets were standardized by their ID and gene symbols in the UniProtKB database (<http://www.uniprot.org/>) [17].

Information on AR-associated targets was retrieved from the therapeutic target disease (<http://db.idrblab.net/ttd/>), DrugBank (<https://www.drugbank.ca>), and DisGeNET (<https://www.disgenet.org/>) databases and standardized using the UniProtKB database.

FIGURE 1: Total ion current chromatogram of LC-MS/MS of MFXD.

2.7. Construction of the Target Protein-Protein Interaction (PPI) Network. To determine whether the therapeutic targets of MFXD are associated with AR, we intersected the drug targets and disease targets to obtain the common targets, which were considered potential therapeutic targets.

The common target proteins were used to construct the PPI network on the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) 11.0 platform (<https://string-db.org/>) using the minimum required interaction score of 0.400. Subsequently, the topological property of the PPI network was analyzed using plugins in Cytoscape 3.7.2. Genes were ranked to define hub genes using cytoHubba with the maximal clique centrality (MCC) algorithm. The module was extracted by MCODE using a node score cutoff of 0.2 and K-core of 2.

2.8. Target Pathway and Enrichment Analysis. To analyze the gene ontology (GO) functional annotations and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment of genes and their roles in signal transduction, the Database for Annotation, Visualization, and Integrated Discovery (DAVID 6.8) was employed. DAVID is an online analytical program that provides a comprehensive set of functional annotation tools to explore the biological functions of genes from gene lists [18]. DAVID can identify and describe the biological processes, cellular components, molecular functions, and pathways that are associated with genes of interest.

2.9. Construction of Compound-Target-Pathway Networks. To understand the underlying mechanism of MFXD in AR, a large-scale combinatorial network was established by integrating data obtained on drug information, drug-target interaction, and target-related pathway interactions. Through the hierarchical network, we characterized the relationships and pathways targeted by MFXD in AR.

3. Results and Discussion

3.1. Analysis of Chemical Compounds from MFXD. The total ion chromatogram of MFXD is shown in Figure 1. This was matched with the OTCML database, jointly constructed by Thermo Scientific and Tsinghua University as a reference for compound identification. Using electrostatic field orbital trap high-resolution MS for fragment MS acquisition, more than 1,200 reference compounds of TCM have been collected in this database. More than 7,000 second-order MS images of the highest quality are available, enabling the rapid and accurate characterization of TCM components and natural products. A total of 24 compounds in MFXD were identified through chromatogram matching. Table 1 shows retention time, experimental and calculated m/z values, molecular formulas, errors in parts per million (ppm), and the major MS/MS fragments. The mass error of all identified compounds was less than 5 ppm.

If a compound is poorly absorbed following oral administration, the pharmacological effects may not be realized, even if the compound has potent effects on the pharmacological target *in vitro* [19]. In this study, Caco-2, OB limits F (20% and 30% bioavailability), and HIA were used to assess the components identified in MFXD. The results from OB and MS were combined to select compounds that were considered to be orally bioactive in the decoction prepared from MFXD. Table 2 presents the ADMET properties of the 24 components identified in MFXD. Most of the compounds showed favorable absorption properties.

3.2. Construction and Analysis of the Component-Target Interaction Network. The TCMSP database contains 499 Chinese herbs with 19,384 compounds, 3,311 targets, and 837 associated diseases [20]. BindingDB is an experimental protein-small molecule database for virtual compound screening based on maximal chemical similarity and support

TABLE 1: Results of LC-MS/MS analysis of MFXD.

No.	Retention time	Theoretical m/z	Measured m/z	Error ppm	Molecular formula	Major MS/MS fragments	Compound
1	3.78	170.0215	170.0211	-2.3526	C ₇ H ₆ O ₅	169.0135 125.0239 97.0291 79.0187	Gallic acid
2	4.02	151.0997	151.0992	-3.3091	C ₉ H ₁₃ NO	134.0965 117.0698 115.0543	Cathine
3	4.03	165.1154	165.1158	2.4226	C ₁₀ H ₁₅ NO	148.1024 133.0804 117.0619	Ephedrine
4	4.11	271.1208	271.1199	-3.3196	C ₁₆ H ₁₇ NO ₃	270.1133 162.0554 107.0498	Higenamine
5	4.12	165.1154	165.1149	-3.0282	C ₁₀ H ₁₅ NO	132.1010 114.8160 91.1290	Pseudoephedrine
6	4.30	179.1310	179.1316	3.3495	C ₁₁ H ₁₇ NO	180.1383 162.1277 117.0700 72.0809	Methylephedrine
7	4.48	594.1585	594.1578	-1.1781	C ₂₇ H ₃₀ O ₁₅	577.1541 457.1118 379.0798 337.0703	Vicenin-2
8	4.75	290.0790	290.0796	2.0684	C ₁₅ H ₁₄ O ₆	289.0715 245.0815 203.0708 109.0289	Catechin
9	5.25	578.1636	578.1623	-2.2485	C ₂₇ H ₃₀ O ₁₄	577.2036 431.0986 285.0396	Kaempferitrin
10	5.42	432.1057	432.1051	-1.3886	C ₂₁ H ₂₀ O ₁₀	433.1122 415.1014 313.0701 283.0597	Vitexin
11	5.57	164.0474	164.0482	4.8766	C ₉ H ₈ O ₃	163.0393 119.0496 93.0341	p-Coumaric acid
12	5.97	302.0427	302.0492	2.1520	C ₁₅ H ₁₀ O ₇	245.0447 152.0185 150.9975	Quercetin
13	6.33	272.0685	272.0679	-2.2053	C ₁₅ H ₁₂ O ₅	271.0613 151.0032 119.0497 93.0342	Naringenin chalcone
14	6.35	162.0317	162.0312	-3.0858	C ₉ H ₆ O ₃	161.0237 133.0288 78.0768	Umbelliferone
15	6.98	589.2887	589.2889	3.3939	C ₃₁ H ₄₃ NO ₁₀	540.2580 508.2311 105.0331	Benzoylmesaconine
16	7.67	218.1671	218.1665	-2.7502	C ₁₅ H ₂₂ O	219.1738 201.0905 145.1008 135.1165	Germacrone
17	7.83	146.0368	146.0365	-2.0543	C ₉ H ₆ O ₂	119.0488 103.0538 91.0538	Coumarin

TABLE 1: Continued.

No.	Retention time	Theoretical m/z	Measured m/z	Error ppm	Molecular formula	Major MS/MS fragments	Compound
18	8.00	194.0579	194.0581	1.0306	C ₁₀ H ₁₀ O ₄	193.0502 177.0542 134.0363	Ferulic acid
19	10.28	615.3044	615.3030	-2.2753	C ₃₃ H ₄₅ NO ₁₀	556.2893 524.2627 338.1745 105.0333	Hypaconitine
20	11.23	629.3200	629.3193	-1.1123	C ₃₄ H ₄₇ NO ₁₀	570.3052 538.2784 105.0331	Deoxyaconitine
21	11.83	232.1463	232.1457	-2.5846	C ₁₅ H ₂₀ O ₂	215.1791 159.1165 145.1009 95.0853	Atractylenolide II
22	12.84	250.1569	250.1560	-3.5977	C ₁₅ H ₂₂ O ₃	233.1522 191.1428 95.0852 71.0128	Nardosinone
23	13.88	208.1099	208.1094	-2.4026	C ₁₂ H ₁₆ O ₃	191.0700 176.0465 168.0779	β -Asarone
24	15.94	278.2246	278.2241	-1.7971	C ₁₈ H ₃₀ O ₂	109.1009 95.0852 81.0696	Linolenic acid

TABLE 2: ADME profile of the compounds from MFXD.

Compounds	Caco-2	HIA	F20	F30
Gallic acid	-5.767	0.431	0.673	0.616
Cathine	-4.783	0.877	0.851	0.869
Ephedrine	-4.956	0.902	0.853	0.879
Higenamine	-5.293	0.538	0.226	0.386
Pseudoephedrine	-4.956	0.902	0.853	0.879
Methylephedrine	-4.477	0.809	0.701	0.707
Vicenin-2	-6.624	0.226	0.447	0.253
Catechin	-6.495	0.400	0.488	0.404
Kaempferitrin	-6.364	0.399	0.584	0.325
Vitexin	-6.317	0.263	0.494	0.287
p-Coumaric acid	-4.892	0.745	0.699	0.536
Quercitrin	-6.469	0.155	0.515	0.242
Naringenin chalcone	-5.198	0.472	0.596	0.519
Umbelliferone	-4.601	0.797	0.534	0.441
Benzoylmesaconine	-6.087	0.301	0.332	0.41
Germacone	-4.378	0.768	0.661	0.625
Coumarin	-4.142	0.848	0.288	0.257
Ferulic acid	-4.943	0.635	0.680	0.509
Hypaconitine	-5.513	0.343	0.265	0.350
Deoxyaconitine	-5.469	0.349	0.261	0.355
Atractylenolide II	-4.35	0.866	0.564	0.549
Nardosinone	-4.353	0.826	0.633	0.585
β -Asarone	-4.379	0.763	0.722	0.681
Linolenic acid	-4.729	0.805	0.568	0.396

vector machine methods [21]. We screened the targets from the TCMSP and BindingDB databases for the 24 active compounds. A total of 198 targets were obtained after the deletion of redundant hits (113 from TCMSP and 138 from BindingDB).

To visualize the relationship between compounds and their targets, we constructed a compound-target interaction network (Figure 2). This network had a density of 0.022 with a characteristic path length of 3.396 and an average number of 4.918 neighbors. In the compound-target network, multiple compounds could act on the same target protein and a single compound could be associated with multiple target proteins. For instance, prostaglandin G/H synthase 2 (PTGS2-P35354) and sodium-dependent noradrenaline transporter (SLC6A2-P23975) represented the hub nodes with a high degree of distribution, whereas peripheral nodes, such as gallic acid, interacted with the progesterone receptor (PGR-P06401) and represented a lower degree of distribution. These results were consistent with the common characteristics of TCM, in which multiple compounds and multiple targets are observed.

3.3. Construction and Analysis of the Target PPI Network. Through the comparative analysis of 198 component targets and AR-related disease targets, we identified 37 common potential targets for MFXD in AR (Table S1). The STRING database is a commonly used tool for predicting PPI and producing integrated and objective association networks [22]. Using the common protein targets as input for network visualization, a diversified PPI network was created (Figure 3(a)). The network systematically summarized the interactions of MFXD targets associated with AR treatment. PSIP1 was not analyzed in the PPI network, as it does not interact with other proteins. The network shows viable protein target nodes ($n=36$) connected by edges ($n=135$)

FIGURE 2: Compound-compound target network of MFxD consists of 24 compounds and 198 compound-target nodes (the yellow rectangles are the compounds and the red triangle targets are compound targets).

with an average node degree of 7.5 and average local clustering coefficient of 0.548. The PPI enrichment p value was less than 1.0×10^{-16} ; thus, proteins have more interactions among themselves than would be expected for a random set of proteins of similar size drawn from the genome. Such a significant enrichment indicated that the proteins are at least partially biologically connected as a group.

The genes ranked by the MCC algorithm were selected using the cytoHubba plugin. The predicted top 10 contributing hub genes were *TNF*, *PPARG*, *ALB*, *PTGS2*, *IL-10*, *ACTB*, *NR3C1*, *ACE*, *SERPINE1*, and *AHR*, which were considered crucial targets of MFxD against AR.

Two significant modules were selected from the PPI network by MCODE (Figures 3(b) and 3(c)). For module 1, the genes were significantly enriched in the nuclear factor- κ B (NF- κ B) signaling pathway and tumor necrosis factor (TNF) signaling pathway. Cluster 2 genes were significantly enriched in the T-cell receptor signaling pathway. These data suggested that MFxD likely acts on AR through all three signaling pathways.

3.4. DAVID Pathway Analysis. To further investigate the multiple mechanisms of MFxD at a systematic level, 37 common genes were uploaded into DAVID 6.8. Functional

association clustering analysis discovered 14 annotation clusters, and the highest enrichment score was 4.07. The top 20 terms in molecular function, cellular component, and biological process are presented in Figures 4(a)–4(c), respectively.

GO enrichment analysis showed that the target genes were expressed in the plasma membrane, cell surface, cell membrane, and other cell compartments. At the molecular level, the target genes were involved in drug binding, enzyme binding, G-protein acetylcholine receptor activity, and steroid binding. At the cellular level, they were related to cell apoptosis, proliferation, and migration. Moreover, biological processes were also enriched with inflammation-related terms. AR is a chronic inflammatory disease that involves the release of various inflammatory mediators [1]. Therefore, the inhibition of the inflammatory response is a therapeutic strategy for AR.

KEGG pathway annotation showed that 31 of the 37 (86.1%) potential target genes were enriched and involved in 153 pathways associated with the immune system, cardiovascular system, cancer, inflammation, and diabetes. As AR is an allergic disease, pathways that are associated with the immune system and inflammation were selected (Figure 4(d)). For example, the Fc epsilon RI, B-cell receptor, T-cell receptor, and Toll-like receptor signaling pathways are

FIGURE 3: The protein-protein interaction (PPI) network and significant module constructed by the STRING database and Cytoscape 3.7.2. Node, target proteins; lines, interactions between proteins. (a) PPI of the common targets related to AR interacting with MFXD molecules. (b, c) Significant module selected from PPI.

involved in the regulation of the immune system and the TNF and NF- κ B signaling pathways are involved in inflammation. We also identified the PI3K/AKT, cAMP, and AMPK signaling pathways in this analysis. The PI3K/AKT signaling pathway is important for cell growth, differentiation, metabolism, survival, and apoptosis [23]. Recent research has revealed that the PI3K-AKT signaling pathway regulates mast cell activity and is modulated in AR [24, 25]. Moreover, the central and peripheral regulation of energy homeostasis relies on the cAMP signaling pathway [26]. KEGG pathway analysis showed that the active components of MFXD act on the gene nodes within the PI3K/AKT and cAMP signaling pathways (Figure 5). These data are consistent with the multiple effects that TCM has on different signaling and cellular pathways [27].

Comparative analysis of these KEGG pathways revealed that, among the 37 potential target genes identified, genes that were repeatedly associated with these pathways were *PIK3CG*, *TNF*, *PTGS2*, *CHRM2*, *CHRM1*, *GSK3B*, *ADRB1*, *CHRM5*, *CHRM3*, and *HSP90AB1*.

3.5. Compound-Target-Pathway Network Analysis of MFXD.

Chinese herbal formulas can contain dozens, or even hundreds, of compounds, and each compound can act on one or multiple targets to exert synergistic therapeutic effects [28]. To directly explore potential synergistic relationships, a compound-target-pathway combination network was constructed

(Figure 6). This network revealed that MFXD contains multiple compounds that have multiple targets within multiple pathways that are associated with AR treatment. For example, quercetin acted on 14 targets (such as P48736, P22301, Q75475, and P08684) and gallic acid acted on three targets (P23219, P35354, and P48736). P48736 was associated with both quercetin and gallic acid. Using network topological analysis, the top 10 compounds that may make major contributions to AR treatment are presented in descending order: quercetin, pseudoephedrine, ephedrine, β -asarone, methylephedrine, α -linolenic acid, cathine, ferulic acid, nardosinone, and higenamine. Quercetin can stimulate the immune system, inhibit the release of histamine, decrease the production of proinflammatory cytokines, increase the synthesis of leukotrienes, restrain the formation of IgE antibody, and improve the Th1/Th2 balance by participating in multiple signal pathways [29]. All these mechanisms of action contribute to the anti-inflammatory and immunomodulatory properties of quercetin, which can be effectively utilized in the treatment of AR, as shown in an animal model [30]. Gallic acid alleviates nasal inflammation via the activation of Th1 and inhibition of Th2 and Th17 cells and has immunomodulatory effects [31]. α -Linolenic acid dampens AR through the eosinophilic production of 15-hydroxyeicosapentaenoic acid [32], and ephedrine has been used as a nasal wash for AR treatment [33].

Most of the compounds, such as kaempferitrin and pseudoephedrine, interact with PTGS2 (P35354). PTGS2 is responsible for the production of inflammatory

FIGURE 4: GO enrichment and KEGG pathway analysis for targets of MFXD constructed by DAVID 6.8. The order of importance was ranked from the top to bottom by $-\log_{10}(P \text{ value})$ with bar charts. The number of targets sticks into each term with line charts. Go analysis was done under the categories of (a) molecular function, (b) cellular component, (c) biological process, and (d) KEGG enrichment pathway. GCAR stands for G-protein-coupled acetylcholine receptor.

FIGURE 5: DAVID pathway analysis. (a) PI3K/Akt signaling pathway. (b) cAMP signaling pathway. The stars indicate the targets where the molecules interact.

FIGURE 6: The pharmacological network (yellow diamonds, compounds; red ellipse, targets; blue triangle, pathway).

prostaglandin E2, which inhibits T regulatory cell differentiation to induce AR-related inflammation [34]. We also discovered compounds that acted together on the targets P01375 and P48736 to regulate the Fc epsilon RI signaling pathway. Gallic acid was observed to interact with PIK3CG (P48736), a key protein that activates the B-cell receptor, T-cell receptor, and Toll-like receptor signal pathways. Finally, targets such as P48736, P01375, P48736, P01375, and P49841, which may provide protection against AR, interacted with most of the compounds.

4. Conclusion

Unlike Western medicines, TCMs are commonly prescribed as herbal formulas that contain a mixture of herbs. Each herb may contain many active ingredients that have single or multiple targets; thus, it is difficult to pinpoint the mechanisms of action of TCM. Network pharmacology shares the core concepts of the holistic philosophy of TCM and meets the requirements to treat complex diseases systematically [35]. However, in the traditional research of network pharmacology, the compounds are mostly collected from databases. Some compounds cannot be detected in the decoction, which may yield false positive results.

In this study, LC-MS/MS identification of compounds in the decoction followed by network pharmacology analyses provided insights into the mechanism of MFXD in the treatment of AR. In total, 24 bioactive compounds were identified in MFXD and 37 common targets were obtained

and analyzed. The results indicated that MFXD was effective in the treatment of AR by regulating key pathways, including the Fc epsilon RI, B-cell receptor, Toll-like receptor, NF- κ B, T-cell receptor, PI3K-AKT, cAMP, and AMPK signaling pathways. Ten compounds in the decoction prepared from MFXD were identified as candidates that could target AR.

These results reduce the prediction range, increase the accuracy of the prediction results, and provide important information for further pharmacological investigations on MFXD. This method, LC-MS/MS for bioactive compound identification followed by network pharmacology analyses, can increase the understanding of the mechanisms of Chinese herbal formulas and promote drug research and development.

Data Availability

The data used to support the findings of this study are included within the supplementary materials.

Conflicts of Interest

The authors report no conflicts of interest in this study.

Acknowledgments

This work was supported by the Natural Science Foundation of Guangdong Province (grant number 2017A030313679), Science and Technology Plan of Guangdong Province (grant number 2017B030314078), and Science and Technology Plan

of Guangzhou City (grant number 201707010042). The authors thank Editage for English language assistance.

Supplementary Materials

Table S1: information on 37 therapeutic targets in MFXD acting directly on AR. (*Supplementary Materials*)

References

- [1] Y. Alsuleimani and M. Walker, "Allergic rhinitis and its pharmacology," *Pharmacology & Therapeutics*, vol. 114, no. 3, pp. 233–260, 2007.
- [2] Y. Zhang and L. Zhang, "Increasing prevalence of allergic rhinitis in China," *Allergy, Asthma & Immunology Research*, vol. 11, no. 2, pp. 156–169, 2019.
- [3] J. L. Brozek, J. Bousquet, I. Agache et al., "Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision," *Journal of Allergy and Clinical Immunology*, vol. 140, no. 4, pp. 950–958, 2017.
- [4] X. Zhang, F. Lan, Y. Zhang, and L. Zhang, "Chinese herbal medicine to treat allergic rhinitis: evidence from a meta-analysis," *Allergy, Asthma & Immunology Research*, vol. 10, no. 1, pp. 34–42, 2018.
- [5] Y. Ikeda, O. T. Iijima, A. Iizuka et al., "Anti-inflammatory effects of mao-bushi-saishin-to in mice and rats," *The American Journal of Chinese Medicine*, vol. 26, no. 2, pp. 171–179, 1998.
- [6] Y. Ikeda, A. Iizuka, S. Amagaya, A. Ishige, Y. Komatsu, and E. Fujihira, "Anti-type I allergic mechanisms of mao-bushi-saishin-to in mice," *The Japanese Journal of Pharmacology*, vol. 82, no. 1, pp. 29–33, 2000.
- [7] M. Ren, Q. Tang, F. Chen, X. Xing, Y. Huang, and X. Tan, "Mahuang Fuzi Xixin decoction attenuates Th1 and Th2 responses in the treatment of ovalbumin-induced allergic inflammation in a rat model of allergic rhinitis," *Journal of Immunology Research*, vol. 2017, Article ID 8254324, 12 pages, 2017.
- [8] F. Tang, Q. Tang, Y. Tian, Q. Fan, Y. Huang, and X. Tan, "Network pharmacology-based prediction of the active ingredients and potential targets of Mahuang Fuzi Xixin decoction for application to allergic rhinitis," *Journal of Ethnopharmacology*, vol. 176, pp. 402–412, 2015.
- [9] S. I. Berger and R. Iyengar, "Network analyses in systems pharmacology," *Bioinformatics*, vol. 25, no. 19, pp. 2466–2472, 2009.
- [10] R. Zhang, X. Zhu, H. Bai, and K. Ning, "Network pharmacology databases for traditional Chinese medicine: review and assessment," *Frontiers in Pharmacology*, vol. 10, no. 123, 2019.
- [11] H. Yuan, Q. Ma, H. Cui et al., "How can synergism of traditional medicines benefit from network pharmacology?" *Molecules*, vol. 22, p. 11357, 2017.
- [12] B. Boezio, K. Audouze, P. Ducrot, and O. Taboureau, "Network-based approaches in pharmacology," *Molecular Informatics*, vol. 36, no. 10, Article ID 1700048, 2017.
- [13] J. Tang and T. Aittokallio, "Network pharmacology strategies toward multi-target anticancer therapies: from computational models to experimental design principles," *Current Pharmaceutical Design*, vol. 20, no. 1, pp. 23–36, 2014.
- [14] P. Csermely, V. Agoston, and S. Pongor, "The efficiency of multi-target drugs: the network approach might help drug design," *Trends in Pharmacological Sciences*, vol. 26, no. 4, pp. 178–182, 2005.
- [15] J. Dong, N. Wang, Z. Yao et al., "ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database," *Journal of Cheminformatics*, vol. 10, no. 1, 2018.
- [16] M. Rask-Andersen, M. S. Almén, and H. B. Schiöth, "Trends in the exploitation of novel drug targets," *Nature Reviews Drug Discovery*, vol. 10, no. 8, pp. 579–590, 2011.
- [17] A. Bateman, M. Martin, S. Orchard et al., "UniProt: a worldwide hub of protein knowledge," *Nucleic Acids Research*, vol. 47, no. D1, pp. D506–D515, 2019.
- [18] D. W. Huang, B. T. Sherman, and R. A. Lempicki, "Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources," *Nature Protocols*, vol. 4, no. 1, pp. 44–57, 2009.
- [19] B. J. Aungst, "Optimizing oral bioavailability in drug discovery: an overview of design and testing strategies and formulation options," *Journal of Pharmaceutical Sciences*, vol. 106, no. 4, pp. 921–929, 2017.
- [20] J. Ru, P. Li, J. Wang et al., "TCMSP: a database of systems pharmacology for drug discovery from herbal medicines," *Journal of Cheminformatics*, vol. 6, no. 13, 2014.
- [21] M. K. Gilson, T. Liu, M. Baitaluk, G. Nicola, L. Hwang, and J. Chong, "BindingDB in 2015: a public database for medicinal chemistry, computational chemistry and systems pharmacology," *Nucleic Acids Research*, vol. 44, no. D1, pp. D1045–D1053, 2016.
- [22] D. Szklarczyk, A. L. Gable, D. Lyon et al., "STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets," *Nucleic Acids Research*, vol. 47, no. D1, pp. D607–D613, 2019.
- [23] J. Á. F. Vara, E. Casado, J. de Castro, P. Cejas, C. Belda-Iniesta, and M. González-Barón, "PI3K/Akt signalling pathway and cancer," *Cancer Treatment Reviews*, vol. 30, no. 2, pp. 193–204, 2004.
- [24] Q. Zeng, X. Luo, M. Han, W. Liu, and H. Li, "Leptin/osteopontin axis regulated type 2t helper cell response in allergic rhinitis with obesity," *EBioMedicine*, vol. 32, pp. 43–49, 2018.
- [25] H. Lin, C. Zheng, J. Li, C. Yang, and L. Hu, "Lentiviral shRNA against KCa3.1 inhibits allergic response in allergic rhinitis and suppresses mast cell activity via PI3K/AKT signaling pathway," *Scientific Reports*, vol. 5, no. 1, 2015.
- [26] K. Ravnskjaer, A. Madiraju, and M. Montminy, "Role of the cAMP pathway in glucose and lipid metabolism," *Handbook of Experimental Pharmacology*, vol. 233, pp. 29–49, 2016.
- [27] L. Yan, Y.-M. Lao, and J.-G. Jiang, "Action mechanisms of Chinese herbal compound at the molecular level," *Letters in Drug Design & Discovery*, vol. 6, no. 5, pp. 397–402, 2009.
- [28] W. Jia, W.-Y. Gao, Y.-Q. Yan et al., "The rediscovery of ancient Chinese herbal formulas," *Phytotherapy Research*, vol. 18, no. 8, pp. 681–686, 2004.
- [29] J. Mlcek, T. Jurikova, S. Skrovanekova, and J. Sochor, "Quercetin and its anti-allergic immune response," *Molecules*, vol. 21, no. 5, p. 623, 2016.
- [30] M. Sagit, H. Polat, S. G. Gurgen, E. Berk, S. Guler, and M. Yasar, "Effectiveness of quercetin in an experimental rat model of allergic rhinitis," *European Archives of Oto-Rhino-Laryngology*, vol. 274, no. 8, pp. 3087–3095, 2017.
- [31] Y. Fan, C. H. Piao, E. Hyeon et al., "Gallic acid alleviates nasal inflammation via activation of Th1 and inhibition of Th2 and Th17 in a mouse model of allergic rhinitis," *International Immunopharmacology*, vol. 70, pp. 512–519, 2019.
- [32] K. Sawane, T. Nagatake, K. Hosomi et al., "Dietary omega-3 fatty acid dampens allergic rhinitis via eosinophilic

production of the anti-allergic lipid mediator 15-Hydroxy-yeicosapentaenoic acid in mice,” *Nutrients*, vol. 11, no. 12, 2019.

- [33] W. A. Shaikh, “Ephedrine-saline nasal wash in allergic rhinitis,” *Journal of Allergy and Clinical Immunology*, vol. 96, no. 5, pp. 597–600, 1995.
- [34] L. Li, K. Guan, Y. Zhou, J. Wu, Y. Wang, and W. Wang, “Prostaglandin E2 signal inhibits T regulatory cell differentiation during allergic rhinitis inflammation through EP4 receptor,” *The World Allergy Organization Journal*, vol. 12, no. 12, Article ID 100090, 2019.
- [35] S. Li and B. Zhang, “Traditional Chinese medicine network pharmacology: theory, methodology and application,” *Chinese Journal of Natural Medicines*, vol. 11, no. 2, pp. 110–120, 2013.